iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
Mavyret + Sofosbuvir (RBV) for Sof/Vel/Vox Failures
  Glecaprevir/pibrentasvir & sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an NS5A inhibitor containing antiviral regimen


Excellent Efficacy and Safety of Sofosbuvir, Glecaprevir, Pibrentasvir and Ribavirin for Retreatment of Chronic Hepatitis C after Sofosbuvir, Velpatasvir and Voxilaprevir Failure SF


Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients
Sofosbuvir + Glecaprevir/Pibrentasvir (G/P) in patients with difficult to treat HCV infection. Final results of the French compassionate use



  iconpaperstack View Older Articles   Back to Top   www.natap.org